NCT02074566View on ClinicalTrials.gov

Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

NACompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

August 14, 2014

Primary Completion Date

March 8, 2018

Study Completion Date

February 13, 2019

Conditions
Atrial Fibrillation
Interventions
OTHER

Cryoballoon ablation

PVI using cryoballoon

Trial Locations (2)

7500 KA

Medisch Spectrum Twente, Enschede

6229 HX

Maastricht University Medical Centre, Maastricht

All Listed Sponsors
collaborator

Thorax Centrum Twente

OTHER

collaborator

Academisch Ziekenhuis Maastricht

OTHER

lead

Harald Verheij

OTHER

NCT02074566 - Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study | Biotech Hunter | Biotech Hunter